858 Therapeutics: Funding, Investors & Team (Sep 2026)
858 Therapeutics is a biotechnology company that concentrates on finding small molecule treatments for new targets in the fields of oncology and immunology. The company prioritizes creative methods in synthetic lethality, innate immunity, and RNA modulation. Its primary initiative is a PARG inhibitor that is currently being developed in early clinical stages.
858 Therapeutics has raised $75.2M across 2 funding rounds on record, the most recent a Series B of $50.0M announced in Sep 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
858 Therapeutics Company Profile and Key Stats
Latest funding round on record: Sep 2024.
858 Therapeutics Funding Rounds
858 Therapeutics raised $25.2M in an undisclosed round announced in Jul 2024.
2 months later, a Series B of $50.0M was announced in Sep 2024.
858 Therapeutics Founders and Leadership Team
Contact details for the 858 Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →858 Therapeutics Funding Compared to Other Biotechnology Startups
858 Therapeutics' latest round of $50.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like 858 Therapeutics in Biotechnology and San Diego
Companies Similar to 858 Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
858 Therapeutics Funding FAQs
What does 858 Therapeutics do?
858 Therapeutics is a biotechnology company that concentrates on finding small molecule treatments for new targets in the fields of oncology and immunology. The company prioritizes creative methods in synthetic lethality, innate immunity, and RNA modulation. Its primary initiative is a PARG inhibitor that is currently being developed in early clinical stages.
How much funding has 858 Therapeutics raised?
858 Therapeutics has raised $75.2M across 2 rounds on record. The most recent is a Series B of $50.0M announced in Sep 2024.
When did 858 Therapeutics last raise funding?
858 Therapeutics' most recent funding round on record is a Series B of $50.0M, announced in Sep 2024.
Who founded 858 Therapeutics?
FundedIQ lists Jeffrey Stafford (Founder) at 858 Therapeutics.
Where is 858 Therapeutics headquartered?
858 Therapeutics is based in San Diego, California, United States.
How many employees does 858 Therapeutics have?
858 Therapeutics is in the 11-50 employee band.
How does 858 Therapeutics' funding compare to other Biotechnology startups?
858 Therapeutics' latest round of $50.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's 858 Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for 858 Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.